HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

T-DXd Yields iDFS Improvement vs T-DM1 in High-Risk HER2+ Early Breast Cancer After Neoadjuvant Therapy

September 29th 2025

Trastuzumab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival vs trastuzumab emtansine in HER2-positive early breast cancer.

The OncFive: Top Oncology Articles for the Week of 9/21

September 27th 2025

Imlunestrant joins the treatment arsenal for ESR1-mutated metastatic breast cancer, T-DXd doublet gets priority review in HER2+ breast cancer, and more.

Breast Cancer Experts: Key ADC Developments and CDK 4/6 Inhibitor Updates Set to Dominate ESMO 2025

September 25th 2025

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.

FDA Grants Priority Review to First-Line T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer

September 24th 2025

Frontline T-DXd plus pertuzumab is under FDA priority review for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.

New T-DXd Data Have the Potential to Reorder ADC Sequencing in HER2+ Breast Cancer

September 22nd 2025

Naoto T. Ueno, MD, PhD, FACP, discusses treatment sequencing considerations in HER2+ advanced or metastatic breast cancer.

T-DXd Shows Real-World Efficacy in HER2+ and HER2-Low/Zero Breast Cancer Brain Metastases

September 16th 2025

T-DXd demonstrated durable systemic and intracranial responses in patients with HER2-positive, -low, and -zero breast cancer brain metastases.

Trastuzumab Pamirtecan Hits Phase 3 PFS End Point in HER2+ Metastatic Breast Cancer

September 12th 2025

Trastuzumab pamirtecan improved progression-free survival in HER2-positive advanced breast cancer after prior trastuzumab and taxane-based chemotherapy.

FDA Grants Fast Track Designation to GLSI-100 in HLA-A*02+, HER2+ Breast Cancer

September 10th 2025

GLSI-100 received fast track designation from the FDA for patients with HLA-A*02- and HER2-positive breast cancer after SOC therapy.

Dr Mouabbi on Data From the CompassHER2 pCR Trial in HER2+ Breast Cancer

September 9th 2025

Jason Aboudi Mouabbi, MD, discusses neoadjuvant multi-agent chemotherapy in HER2+ breast cancer.

Dr Tarantino on the Efficacy of Adjuvant THP in HER2+ Breast Cancer

September 8th 2025

Paolo Tarantino, MD, PhD, discusses the efficacy and safety of adjuvant THP in patients with stage II to IIIA HER2-positive breast cancer.

Ventana Assay Earns CE IVDR Approval in EU as Companion Diagnostic in HER2-Expressing Breast and Biliary Tract Cancers

September 5th 2025

The VENTANA HER2 (4B5) test earned CE-IVDR approval in Europe to assess HER2 status in metastatic breast cancer and biliary tract cancer.

Ongoing Trials and Practical Insights Shape CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer

August 30th 2025

Neelam V. Desai, MD, discusses the role of first-line CDK4/6 inhibitors in HR-positive, HER2-negative and HER2-positive metastatic breast cancer.

Dr Mouabbi on Areas for Further Investigation in HER2+ Breast Cancer

August 28th 2025

Jason A. Mouabbi, MD, discusses unmet needs and areas requiring further investigation in HER2-positive advanced breast cancer.

Researchers Build Real-World External Control Arm to Accelerate HER2+ Breast Cancer Drug Development

August 26th 2025

Jessica Paulus, ScD, discusses the incorporation of an external control arm into the analysis of a phase 2 trial in HER2-positive breast cancer.

Trastuzumab Deruxtecan Approved in Japan for HER2-Low or -Ultralow Metastatic Breast Cancer

August 26th 2025

Trastuzumab deruxtecan has been approved in Japan for patients with HR+, HER2-low or -ultralow metastatic breast cancer.

Paulus on Research With a Real-World External Control Arm in HER2+ Breast Cancer

August 25th 2025

Jessica Paulus, ScD, discusses the development of a real-world control arm to inform the utility of findings from a trial in HER2-positive breast cancer.

Dr McCann on the Importance of Integrating Patient Preferences Into Treatment Planning for Patients With HER2+ Breast Cancer

August 25th 2025

Kelly McCann, MD, PhD, discusses the relevance of patient preferences during treatment decision-making for patients with HER2-positive breast cancer.

Chemo-Free Combination of Ribociclib/Trastuzumab/Letrozole Shows PFS Benefit in HR+/HER2+ Breast Cancer

August 19th 2025

Ribociclib plus trastuzumab and an AI produced a median PFS of 30.4 months in patients with hormone receptor–positive, HER2-positive breast cancer.

SHR-A1811 Monotherapy Generates Similar pCR Rate as PCbHP in HER2+ Breast Cancer

August 14th 2025

The antibody-drug conjugate SHR-A1811 demonstrated a comparable pCR rate to SHR-A1811/pyrotinib and PCbHP in HER2-positive breast cancer.

Real-World Data Support Tucatinib-Based Treatment in HER2+ Metastatic Breast Cancer

August 13th 2025

Real-world tucatinib-based regimens were effective in different lines for HER2-positive metastatic breast cancer, including after trastuzumab deruxtecan.